New drug shows promise in limiting brain damage after hemorrhagic stroke

NCT ID NCT05970224

First seen Apr 08, 2026 · Last updated May 16, 2026 · Updated 4 times

Summary

This study tests a new drug called Ir-CPI in 23 adults who have had a bleeding stroke (intracerebral hemorrhage). The goal is to see if adding Ir-CPI to standard care is safe and can reduce further brain injury. Participants receive either Ir-CPI plus standard care or standard care alone, and doctors monitor side effects and brain scans for several weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRACEREBRAL HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AZ Damiaan

    Ostend, West Flanders, 8400, Belgium

  • AZ Groeninge

    Kortrijk, West Flanders, 8500, Belgium

  • AZ Sint-Jan

    Bruges, West Flanders, 8000, Belgium

  • CHU Ambroise Paré

    Mons, Hainaut, 7000, Belgium

  • Clinique CHC MontLégia

    Liège, Belgium

  • HUB Erasme

    Brussels, Brussels Capital, 1070, Belgium

  • UCL St Luc

    Brussels, Brussels Capital, Belgium

  • UZ Brussel

    Brussels, Brussels Capital, Belgium

  • UZ Gent

    Ghent, East Flanders, 9000, Belgium

  • UZ Leuven

    Leuven, Flemish Brabant, Belgium

Conditions

Explore the condition pages connected to this study.